| Title |
Efficacy of an Interleukin-1β Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis
|
|---|---|
| Published in |
Pediatric Cardiology, October 2012
|
| DOI | 10.1007/s00246-012-0532-0 |
| Pubmed ID | |
| Authors |
Alessandra Scardapane, Antonio Brucato, Francesco Chiarelli, Luciana Breda |
| Abstract |
Pericarditis may recur in up to 30 % of adult patients, but recurrent pericarditis is a rare disease in childhood. The etiology of the initial attack and the causes of recurrences often remain unknown. Recurrent pericarditis is accompanied by a high morbidity rate and may represent a challenge to the clinician due to problems in management. Therapeutic strategies are not specific and include nonsteroidal antiinflammatory drugs, corticosteroids, immunosuppressive drugs, colchicine, and pericardiectomy. Controlled trials have demonstrated that colchicine can reduce the recurrent rate of pericarditis, whereas early corticosteroid therapy promotes recurrences. Anakinra, a recombinant human interleukin-1β receptor antagonist, is a promising new biologic agent for the treatment of autoinflammatory diseases such as cryopyrinopathies, tumor necrosis factor receptor-associated periodic syndrome, and hyperimmunoglobulinemia D with periodic fever syndrome. This report describes an 11-year-old boy successfully treated with anakinra for a steroid-dependent recurrent pericarditis unresponsive to conventional treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Israel | 1 | 3% |
| Unknown | 33 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 21% |
| Researcher | 6 | 18% |
| Student > Ph. D. Student | 4 | 12% |
| Student > Bachelor | 3 | 9% |
| Student > Master | 3 | 9% |
| Other | 8 | 24% |
| Unknown | 3 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 50% |
| Agricultural and Biological Sciences | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Business, Management and Accounting | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 6 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2012.
All research outputs
#20,171,868
of 22,684,168 outputs
Outputs from Pediatric Cardiology
#1,096
of 1,407 outputs
Outputs of similar age
#153,825
of 173,108 outputs
Outputs of similar age from Pediatric Cardiology
#15
of 26 outputs
Altmetric has tracked 22,684,168 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,407 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,108 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.